Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTREPID OLE long-term open-label extension of brazikumab in Crohn's disease
MOH_2021-11-03_010368Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of brazikumab in Crohn's disease (2 arms), sponsored by AstraZeneca. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
brazikumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2021-11-03_010368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-11-03_010368.